Gu, X.; Li, X.; Li, H.; Liu, N.; Xu, Y.; Li, K.; Zhang, J.; Wang, X.; Zhang, X.; Ding, Y.;
et al. Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. Biomedicines 2025, 13, 2180.
https://doi.org/10.3390/biomedicines13092180
AMA Style
Gu X, Li X, Li H, Liu N, Xu Y, Li K, Zhang J, Wang X, Zhang X, Ding Y,
et al. Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. Biomedicines. 2025; 13(9):2180.
https://doi.org/10.3390/biomedicines13092180
Chicago/Turabian Style
Gu, Xiaoting, Xiaohe Li, Hailong Li, Nannan Liu, Ying Xu, Keran Li, Jia Zhang, Xiaoting Wang, Xiaoting Zhang, Yanjie Ding,
and et al. 2025. "Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs" Biomedicines 13, no. 9: 2180.
https://doi.org/10.3390/biomedicines13092180
APA Style
Gu, X., Li, X., Li, H., Liu, N., Xu, Y., Li, K., Zhang, J., Wang, X., Zhang, X., Ding, Y., Zhou, H., Ai, X., & Yang, C.
(2025). Preclinical Safety Profile of Deg-AZM, a Clinical-Stage New Transgelin Agonist: hERG Inhibition Study In Vitro, Cardiovascular–Respiratory Pharmacology, and Single/Repeated-Dose Toxicity in Beagle Dogs. Biomedicines, 13(9), 2180.
https://doi.org/10.3390/biomedicines13092180
